Biologics including Dupilumab and anti-IL-5 agents were associated with a lower probability of pneumonia within the study
MILWAUKEE, Feb. 20, 2026 /PRNewswire/ — Asthma biologics were not found to correlate with any increased risk to respiratory infections, however, some biologics were linked to a decreased risk of pneumonia, according to new research being presented at the 2026 AAAAI Annual Meeting.
“It is reassuring that real-world data confirm findings from clinical trials, showing no increased risk of infection associated with biologic therapies. This is encouraging news for patients with asthma who require treatment with biologics,” lead author said Shane Stone, DO.
Despite previous concerns that biologics targeting type 2 inflammation may…